Anesthesiology and Pain Medicine

Published by: Kowsar

Pain Management in Intensive Care Unit Patients: The Role of Ultra-Short Acting Opioid: Remifentanil

Zahid Hussain Khan 1 , *
Author Information
1 Department of Anesthesiology and Intensive Care, Imam Khomeini Medical Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran
Article information
  • Anesthesiology and Pain Medicine: July 20, 2013, 3 (1); 188-90
  • Published Online: July 1, 2013
  • Article Type: Editorial
  • Received: January 15, 2013
  • Accepted: February 20, 2013
  • DOI: 10.5812/aapm.10299

To Cite: Khan Z H. Pain Management in Intensive Care Unit Patients: The Role of Ultra-Short Acting Opioid: Remifentanil, Anesth Pain Med. 2013 ; 3(1):188-90. doi: 10.5812/aapm.10299.

Copyright © 2013, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Shapiro BA, Warren J, Egol AB, Greenbaum DM, Jacobi J, Nasraway SA, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Society of Critical Care Medicine. Crit Care Med. 1995; 23(9): 1596-600[PubMed]
  • 2. Soliman HM, Melot C, Vincent JL. Sedative and analgesic practice in the intensive care unit: the results of a European survey. Br J Anaesth. 2001; 87(2): 186-92[PubMed]
  • 3. Breen D, Wilmer A, Bodenham A, Bach V, Bonde J, Kessler P, et al. Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care. 2004; 8(1)-30[DOI][PubMed]
  • 4. Karabinis A, Mandragos K, Stergiopoulos S, Komnos A, Soukup J, Speelberg B, et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]. Crit Care. 2004; 8(4)-80[DOI][PubMed]
  • 5. Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993; 79(5): 881-92[PubMed]
  • 6. Westmoreland CL, Hoke JF, Sebel PS, Hug CC, Jr, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology. 1993; 79(5): 893-903[PubMed]
  • 7. Battershill AJ, Keating GM. Remifentanil : a review of its analgesic and sedative use in the intensive care unit. Drugs. 2006; 66(3): 365-85[PubMed]
  • 8. Chalumeau-Lemoine L, Stoclin A, Billard V, Laplanche A, Raynard B, Blot F. Flexible fiberoptic bronchoscopy and remifentanil target-controlled infusion in ICU: a preliminary study. Intensive Care Med. 2013; 39(1): 53-8[DOI][PubMed]
  • 9. Devabhakthuni S, Armahizer MJ, Dasta JF, Kane-Gill SL. Analgosedation: a paradigm shift in intensive care unit sedation practice. Ann Pharmacother. 2012; 46(4): 530-40[DOI][PubMed]
  • 10. Quintard H, Pavlakovic I, Mantz J, Ichai C. Adjunctive remifentanil infusion in deeply sedated and paralyzed ICU patients during fiberoptic bronchoscopy procedure: a prospective, randomized, controlled study. Ann Intensive Care. 2012; 2(1): 29[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments